These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 22552811)

  • 1. Expression levels of HER2/neu and those of collocated genes at 17q12-21, in breast cancer.
    Glynn RW; Miller N; Mahon S; Kerin MJ
    Oncol Rep; 2012 Jul; 28(1):365-9. PubMed ID: 22552811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
    Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
    Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of Caveolin-1, Caveolin-2 and HER2/neu mRNA expression in human breast cancer.
    Sagara Y; Mimori K; Yoshinaga K; Tanaka F; Nishida K; Ohno S; Inoue H; Mori M
    Br J Cancer; 2004 Aug; 91(5):959-65. PubMed ID: 15305200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-time RT-PCR analysis for evaluating the Her2/neu status in breast cancer.
    Cuadros M; Talavera P; López FJ; García-Peréz I; Blanco A; Concha A
    Pathobiology; 2010; 77(1):38-45. PubMed ID: 20185966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
    Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
    Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
    Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
    Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic alterations and protein expression of HER2 and chromosome 17 polysomy in breast cancer.
    Zhu X; Lu Y; Lu H; Yang W; Tu X; Cai X; Zhou X
    Hum Pathol; 2011 Oct; 42(10):1499-504. PubMed ID: 21676436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SLP-2 overexpression could serve as a prognostic factor in node positive and HER2 negative breast cancer.
    Cao W; Zhang B; Li J; Liu Y; Liu Z; Sun B
    Pathology; 2011 Dec; 43(7):713-8. PubMed ID: 22081131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes.
    Smid M; Hoes M; Sieuwerts AM; Sleijfer S; Zhang Y; Wang Y; Foekens JA; Martens JW
    Breast Cancer Res Treat; 2011 Jul; 128(1):23-30. PubMed ID: 20632083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GRB7 protein over-expression and clinical outcome in breast cancer.
    Ramsey B; Bai T; Hanlon Newell A; Troxell M; Park B; Olson S; Keenan E; Luoh SW
    Breast Cancer Res Treat; 2011 Jun; 127(3):659-69. PubMed ID: 20635137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
    Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
    Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M
    Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression levels and clinical-pathological correlations of HER2/neu in primary and metastatic human breast cancer.
    Stefano R; Agostara B; Calabrò M; Campisi I; Ravazzolo B; Traina A; Miele M; Castagnetta L
    Ann N Y Acad Sci; 2004 Dec; 1028():463-72. PubMed ID: 15650272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.
    Kobayashi T; Tsuda H; Moriya T; Yamasaki T; Kikuchi R; Ueda S; Omata J; Yamamoto J; Matsubara O
    Breast Cancer Res Treat; 2010 Oct; 123(3):733-45. PubMed ID: 20020198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Her-2/neu oncogene expression in Puerto Rican females with breast cancer.
    Peredo R; Sastre G; Serrano J; Hunter Mellado R
    Cell Mol Biol (Noisy-le-grand); 2001 Sep; 47(6):1025-32. PubMed ID: 11785652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis.
    Tsiambas E; Karameris A; Dervenis C; Lazaris AC; Giannakou N; Gerontopoulos K; Patsouris E
    JOP; 2006 May; 7(3):283-94. PubMed ID: 16685109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein.
    Recăreanu F; Simionescu C; Georgescu CV; Pirici E
    Rom J Morphol Embryol; 2011; 52(3 Suppl):1059-64. PubMed ID: 22119825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct expressions of microRNAs that directly target estrogen receptor α in human breast cancer.
    Yoshimoto N; Toyama T; Takahashi S; Sugiura H; Endo Y; Iwasa M; Fujii Y; Yamashita H
    Breast Cancer Res Treat; 2011 Nov; 130(1):331-9. PubMed ID: 21755340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of HER2/neu in primary and metastatic breast cancer.
    Tuziak T; Olszewski WP; Olszewski W; Pieńkowski T
    Pol J Pathol; 2001; 52(1-2):21-6. PubMed ID: 11505677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study of HER2/neu status in Qatari women with breast carcinoma.
    Rasul KI; Mohammaed K; Abdalla AS; Chong-Lopez A; Ahmad MA; Al-Homsi MU; Al-Hassan AM; Al-Alosi AS; Bener A
    Saudi Med J; 2003 Aug; 24(8):832-6. PubMed ID: 12939666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.